SRNE News and Press, Sorrento Therapeutics Inc. From 12/09/20

FDA has granted clearance for the commencement of Phase 1 clinical trials of STI-2020 (COVI-AMG TM ) in healthy volunteers and COVID-19 patients with mild symptoms. STI-2020, a monoclonal antibody, has been engineered for ultra-high potency, which potentially translates to a small...

Sorrento Therapeutics (SRNE) perks 9% premarket after receiving CLIA Licensure from the State of California that permits testing of clinical samples.The Company intends to initially focus on testing for SARS-CoV-2 infection but expects to expand to include immuno-oncology tests. Sor...

Intec Pharma (NTEC) +111% after research pact with UK-based GW Pharma.Recon Technology (RCON) +102%.Francesca's Holdings (FRAN) +99% after receiving court approval of first day motions to support ongoing operations.ZW Data Action Technologies (CNET) +101% after opening its firs...

Sorrento receives Clinical Laboratory Improvement Amendments (CLIA) license from the State of California for clinical sample testing Sorrento intends to initially offer three diagnostic tests for SARS-CoV-2 infection: - RT-PCR Emergency Use Authorization (EUA)-approved test usin...

Our experts issued a rare "Double Down" Buy alert on this one stock... Learn more. Investors using the Robinhood platform are known for seeking out stocks that may make big share moves in a short period. As a long-term investor, I'm more interested in stocks that will steadily climb...

Are These The Best Biotech Stocks To Add To Your List Before December? Going into December, the top biotech stocks continue to flourish. It has undoubtedly been the year for biotech companies in the stock market as they are essentially the frontline industry in the fight aga...

SAN DIEGO, Nov. 29, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), is pleased to announce that Dr. Henry Ji, Chairman and CEO, will be participating in the Piper Sandler 32nd Annual Virtual Healthcare Conference. A pre-recorded presentation is made av...

Defense Advanced Research Projects Agency ((DARPA)) co-funded by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) awarded SmartPharm Therapeutics, wholly-owned subsidiary of Sorrento Therapeutics (SRNE) +17% PM, a contract fo...

Initial funding of up to $34 million for the project “Gene Mabs: A Scalable, Economic, Gene-Encoded Protective Antibody Platform Against Coronavirus” (HR0011-21-9-0015) to support the development of an STI-2020-encoded Gene MAb TM through Phase 2 clinical studies. ST...

In this video from Motley Fool Live recorded on Nov. 12, Henry Ji, chairman, president, and CEO of Sorrento Therapeutics (NASDAQ: SRNE) , highlights what investors should expect from the biotech's COVID-19 products in months ahead. Ji also talks about the company's financial sit...